Retrospective investigation of the results of long-term treatment with disease modifying drugs in rheumatoid arthritis

Objective. To investigate effect of different disease modifying drugs (DMARDs) on X-ray progression, functional disability and quality of life in RA patients with disease duration of at least 10 years. Methods. 238 pts with RA (according to ARA 1987 criteria) with the beginning of disease at 1992 or...

Full description

Bibliographic Details
Main Author: D Karateev
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2003-06-01
Series:Научно-практическая ревматология
Subjects:
Online Access:https://rsp.mediar-press.net/rsp/article/view/1221
id doaj-8d0394f29b3c44b0a4ece0ed6dba24e4
record_format Article
spelling doaj-8d0394f29b3c44b0a4ece0ed6dba24e42021-08-02T09:05:33ZrusIMA-PRESS LLCНаучно-практическая ревматология1995-44841995-44922003-06-01413323610.14412/1995-4484-2003-13571161Retrospective investigation of the results of long-term treatment with disease modifying drugs in rheumatoid arthritisD KarateevObjective. To investigate effect of different disease modifying drugs (DMARDs) on X-ray progression, functional disability and quality of life in RA patients with disease duration of at least 10 years. Methods. 238 pts with RA (according to ARA 1987 criteria) with the beginning of disease at 1992 or later (30 male and 208 female) were included. Mean follow up duration was I5,5±6,4 years. X-ray changes were evaluated by Larsen method. Functional disability was assessed by HAQ and quality of life - by RAQol scale. Information about antirheumatic therapy was obtained by questioning of patients and from medical documentation. Results. There was no significant positive effect of DMARDs therapy on X-ray progression. Patients receiving gold salts (tauredon or chrisanol) for a long time had lower HAQ functional index (1,34±0,76 in comparison with 1,74±0,83 in patients without aurotherapy, p<0,0l) and less prominent quality of life decrease according to RAQoL scale (19,2±6,3 in comparison with 22,11:5.8. p<0,05). Other DMARDs had no significant independent positive effect on functional disability and quality of life at the end of long-term follow up. Conclusion. Retrospective evaluation of the results of long-term follow up showed that gold salts remained the drugs of choice in RA.https://rsp.mediar-press.net/rsp/article/view/1221rheumatoid arthritisbasic therapydmardlong-term follow up
collection DOAJ
language Russian
format Article
sources DOAJ
author D Karateev
spellingShingle D Karateev
Retrospective investigation of the results of long-term treatment with disease modifying drugs in rheumatoid arthritis
Научно-практическая ревматология
rheumatoid arthritis
basic therapy
dmard
long-term follow up
author_facet D Karateev
author_sort D Karateev
title Retrospective investigation of the results of long-term treatment with disease modifying drugs in rheumatoid arthritis
title_short Retrospective investigation of the results of long-term treatment with disease modifying drugs in rheumatoid arthritis
title_full Retrospective investigation of the results of long-term treatment with disease modifying drugs in rheumatoid arthritis
title_fullStr Retrospective investigation of the results of long-term treatment with disease modifying drugs in rheumatoid arthritis
title_full_unstemmed Retrospective investigation of the results of long-term treatment with disease modifying drugs in rheumatoid arthritis
title_sort retrospective investigation of the results of long-term treatment with disease modifying drugs in rheumatoid arthritis
publisher IMA-PRESS LLC
series Научно-практическая ревматология
issn 1995-4484
1995-4492
publishDate 2003-06-01
description Objective. To investigate effect of different disease modifying drugs (DMARDs) on X-ray progression, functional disability and quality of life in RA patients with disease duration of at least 10 years. Methods. 238 pts with RA (according to ARA 1987 criteria) with the beginning of disease at 1992 or later (30 male and 208 female) were included. Mean follow up duration was I5,5±6,4 years. X-ray changes were evaluated by Larsen method. Functional disability was assessed by HAQ and quality of life - by RAQol scale. Information about antirheumatic therapy was obtained by questioning of patients and from medical documentation. Results. There was no significant positive effect of DMARDs therapy on X-ray progression. Patients receiving gold salts (tauredon or chrisanol) for a long time had lower HAQ functional index (1,34±0,76 in comparison with 1,74±0,83 in patients without aurotherapy, p<0,0l) and less prominent quality of life decrease according to RAQoL scale (19,2±6,3 in comparison with 22,11:5.8. p<0,05). Other DMARDs had no significant independent positive effect on functional disability and quality of life at the end of long-term follow up. Conclusion. Retrospective evaluation of the results of long-term follow up showed that gold salts remained the drugs of choice in RA.
topic rheumatoid arthritis
basic therapy
dmard
long-term follow up
url https://rsp.mediar-press.net/rsp/article/view/1221
work_keys_str_mv AT dkarateev retrospectiveinvestigationoftheresultsoflongtermtreatmentwithdiseasemodifyingdrugsinrheumatoidarthritis
_version_ 1721236302307786752